Lynkcell Inc.   Report issue

For profit Phase 1
Founded: Sheridan WY United States (2018)
Status: Defunct (2023)

Organization Overview

First Clinical Trial
2018
NCT03644459
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Lynkcell Europe | Lynkcell Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

axitinib (inlyta) (2 trials)

lyn00101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2